NEW DELHI: Serum Institute of India (SII) announced a strategic investment to buy 20% in med tech firm IntegriMedical to advance needle-free injection system technology.
The partnership between SII and IntegriMedical aligns with SII’s vision of ‘health for all’ and IntegriMedical’s mission to ‘transform healthcare globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries and enhancing efficacy of liquid medication via needle-free dispersion, says a company statement.
IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet stream, using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience. N-FIS will be available in the private market, offering patients and healthcare providers an alternative to traditional needle-based injections.
The partnership between SII and IntegriMedical aligns with SII’s vision of ‘health for all’ and IntegriMedical’s mission to ‘transform healthcare globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries and enhancing efficacy of liquid medication via needle-free dispersion, says a company statement.
IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet stream, using mechanical power to effectively and consistently administer biologics and drugs. The innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a pleasant and stress-free experience. N-FIS will be available in the private market, offering patients and healthcare providers an alternative to traditional needle-based injections.
